Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 13.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 929,644 shares of the biopharmaceutical company's stock after purchasing an additional 110,262 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.58% of Vanda Pharmaceuticals worth $4,267,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Quantinno Capital Management LP acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $48,000. Linden Thomas Advisory Services LLC acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth approximately $49,000. XTX Topco Ltd acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $69,000. Zacks Investment Management acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter worth approximately $74,000. Finally, ProShare Advisors LLC raised its holdings in shares of Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 4,599 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.
Insider Transactions at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was purchased at an average cost of $4.40 per share, with a total value of $44,000.00. Following the completion of the purchase, the chief executive officer owned 2,325,731 shares in the company, valued at approximately $10,233,216.40. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stephen Ray Mitchell sold 7,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director directly owned 97,082 shares of the company's stock, valued at approximately $445,606.38. The trade was a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.90% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
VNDA has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Wall Street Zen downgraded Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.
View Our Latest Stock Report on VNDA
Vanda Pharmaceuticals Stock Up 6.8%
Shares of Vanda Pharmaceuticals stock traded up $0.30 during trading on Monday, reaching $4.66. 652,113 shares of the company were exchanged, compared to its average volume of 572,216. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.55. The business has a 50-day moving average price of $4.61 and a 200-day moving average price of $4.53. The firm has a market capitalization of $275.06 million, a price-to-earnings ratio of -4.12 and a beta of 0.72.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. The company had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. On average, equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access